MND / ALS
A brain-computer interface has enabled a man with ALS to speak in real time by converting brain activity directly into a synthetic voice. The investigational system allows the user to communicate with family through a digital vocal tract that simulates speech, enabling him to adjust intonation and even produce simple melodies. Unlike earlier technologies that [...]
During REM sleep, the body enters a state of paralysis. This can pose a danger for patients with weakened diaphragms due to neuromuscular diseases. Now new research published at the ATS 2025 International Conference has shown that antidepressants that suppress REM sleep are associated with improved survival in people with amyotrophic lateral sclerosis (ALS). The [...]
A campaign focused on people with a rare form of terminal illness who are unable to access a groundbreaking new drug, despite it being currently provided for free to the NHS, has reached 10,000 signatures on its petition. The findings show access to tofersen, the first effective new motor neurone disease (MND) treatment for decades, [...]
The Motor Neurone Disease (MND) Association is urging the government to take action as people with a rare form of MND are unable to access a groundbreaking new drug, despite it being currently provided for free to the NHS. Tofersen is the first effective new MND treatment for decades, however, access to the drug has [...]
The Motor Neurone Disease (MND) Association has bolstered its research leadership team to keep pace with the growing opportunities in the MND research space and a drive to fund treatment-focused, personalised and patient centred research. Dr Mike Rogers MBE has been appointed as the Director of Research and Innovation, with Dr Brian Dickie MBE becoming [...]
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that affects motor neurons. The average life span after diagnosis of this incurable disease is two to five years. Now, researchers have identified a new lead: tiny, antenna-like structures 0n cells called primary cilia, which could open a potential new avenue for therapeutic development. Despite extensive [...]
More than 1500 attended the MND Association’s international symposium to hear the latest advances in research for the condition. The annual event is the largest medical and scientific conference on MND and attracted delegates from 48 countries, with 80 per cent of the number attending in person. With a shared passion for MND research and [...]
Research consortium, Answer ALS, and the Alzheimer’s Disease Data Initiative (AD Data Initiative), are embarking on a partnership to integrate the AD Data Initiative’s AD Workbench with Answer ALS’s Neuromine Data Portal. This collaboration will reshape the landscape of neurodegenerative disease research by providing a unified, single access platform for data sharing and analysis. The [...]
The third global, multi-million pound Longitude Prize will be launched in 2025 focusing on Amyotrophic lateral sclerosis (ALS). It will incentivise the use of AI and machine-learning approaches to transform drug discovery for the treatment of ALS, a form of motor neurone disease (MND), opening the door for new treatments across other neurodegenerative diseases. The [...]
Promising new research to develop gene therapy to treat motor neurone disease (MND) and other conditions like dementia has secured major investment. The new potential treatment discovered by a team at University College London (UCL) and backed by the MND Association, My Name’5 Doddie Foundation and LifeArc, has moved one step closer to people living [...]
